Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 11, 595 - 596 (2005)
doi:10.1038/nm0605-595
Validating Stat3 in cancer therapy
James E Darnell Jr1
- The author is at the Rockefeller University, New York, New York 10021, USA. e-mail: darnell@rockefeller.edu
Abstract
The transcription factor STAT3 is overactive in many tumors and has attracted attention as a drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer has been incomplete. The picture in the whole animal now begins to clarify, and it bodes well for this approach (pages 623–629).
Many different genetic defects exist in human cancer cells, posing a great difficulty in devising a widely applicable anticancer strategy. Because it is absent or defective in more than half of all human cancers, the tumor suppressor p53 has attracted much attention.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNature Medicine Article (01 Jun 2005)
Stat3 activation in human endometrial and cervical cancersBritish Journal of Cancer Original Article
